IMV (Formerly Immunovaccine Inc.) to Present at the National Bank Financial Quebec Conference in Toronto
May 25, 2018 16:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, May 25, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that IMV Chief Executive Officer Frederic Ors will...
IMV Inc. (Formerly Immunovaccine Inc.) Announces Q1 2018 Financial Results
May 14, 2018 16:35 ET
|
IMV Inc.
HALIFAX, Nova Scotia, May 14, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (TSX:IMV) (OTCQX:IMMVD), a clinical stage immuno-oncology corporation, today released its financial and operational results for the...
IMV Inc. – Change of ticker on OTCQX from IMMVF to IMMVD
May 10, 2018 10:29 ET
|
IMV Inc.
HALIFAX, Nova Scotia, May 10, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVD), a clinical stage immunotherapy company, announced that its new ticker on OTCQX...
IMV Inc. Commences Trading on the TSX and OTCQX Post-Reverse Stock Split
May 10, 2018 07:05 ET
|
IMV Inc.
HALIFAX, Nova Scotia, May 10, 2018 (GLOBE NEWSWIRE) -- IMV Inc. (“IMV” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVF), a clinical stage immunotherapy company, announced that its common shares...
Immunovaccine Inc. Has Applied to List its Common Shares on Nasdaq, Announces Reverse Stock Split
May 03, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, May 03, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (“Immunovaccine” or the “Corporation”) (TSX:IMV) (OTCQX:IMMVF), a clinical stage immunotherapy company, announced today that...
Immunovaccine Shareholders Approve Share Consolidation at 99.85%
May 01, 2018 16:35 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, May 01, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV)(OTCQX:IMMVF), a clinical stage immuno-oncology corporation, today announced that at the annual and special meeting...
Immunovaccine to Highlight Clinical Data for Its Lead Candidate in Oral Presentation at 54th Annual Meeting of the American Society of Clinical Oncology
April 26, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, April 26, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that its abstract has been selected for...
Immunovaccine and Incyte Expand Clinical Collaboration Evaluating Combination Immunotherapies in Advanced Recurrent Ovarian Cancer
April 24, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, April 24, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it has entered into an agreement...
Immunovaccine to Present at Bloom Burton & Co. Healthcare Investor Conference
April 23, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, April 23, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, announced that Chief Executive Officer Frederic Ors...
Immunovaccine Announces Leading Independent Proxy Advisory Firms Recommend Voting for Share Consolidation Related to Potential Nasdaq Listing
April 17, 2018 07:05 ET
|
Immunovaccine Inc.
HALIFAX, Nova Scotia, April 17, 2018 (GLOBE NEWSWIRE) -- Immunovaccine Inc. (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology corporation, is pleased to announce that Institutional...